Skip to content

The Effects of Dietary Supplementation on Serum Protein Glycosylation

The Effects of Dietary Supplementation on Serum Protein Glycosylation

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05040204
Enrollment
44
Registered
2021-09-10
Start date
2022-06-23
Completion date
2026-11-22
Last updated
2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

dietary supplement

Brief summary

Two randomized double-blind placebo-controlled clinical studies to assess the effects of dietary glycan monomer supplementation on the immune system, especially antibody glycosylation in healthy adults. Immune profiling and glycoproteomics will be performed on serum isolated at these same time points.

Interventions

DIETARY_SUPPLEMENTMonosaccharide Powder

Monosaccharide powder dissolved in water.

DIETARY_SUPPLEMENTPlacebo Comparator

Placebo (glucose powder)

Sponsors

University of California, Davis
Lead SponsorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult men/women (age 18-45) who are in general good health with Body Mass Index (BMI) range of 18.5-25

Exclusion criteria

* Adults younger than 18 or older than 45 years of age * Women who are pregnant, actively nursing or have had a pregnancy within the last year * Women who are peri-menopausal or post-menopausal * Women with irregular menstrual cycles (more frequently than every 21 days or lasts longer than 8 days. Missed, early, or late periods are also considered signs of an irregular cycle) * Women on hormonal contraception, including birth control, hormonal intrauterine device, or contraceptive implant * Individuals with past medical history of an autoimmune condition or malignancy, excluding non-melanoma skin cancer * Individuals with cardiovascular, pulmonary, reproductive, endocrine, metabolic, neurologic, gastrointestinal, hematologic, or infectious diseases of any type * Individuals with diagnosis of galactosemia or congenital disorders of glycosylation * Individuals with phenylketonuria * Individuals currently taking prescription medications, or who have taken prescription medications within the last 3 months * Individuals currently taking over-the-counter medications * Individuals currently taking or who have taken supplements including herbal, protein or vitamin supplements in the last 3 months (e.g. whey protein, St. John's Wort, green tea supplements, biotin, creatine supplements), excluding multivitamins or essential vitamins * Individuals with BMI less than 18.5 or greater than 25 * Individuals with prior history of severe food or drug allergic reactions * Individuals with allergic reaction or adverse reaction to shellfish, N-acetylglucosamine, galactose, Spirulina/chlorella/algae supplements, or arabinose containing compounds/foods/supplements * Individuals with first-degree relative with history of an autoimmune condition * Individuals with social history of current use of tobacco, alcohol or other drugs * Individuals with dietary restrictions (vegetarians are permitted to participate in the study) or atypical exercise patterns, or to whom any of the following dietary habits or characteristics apply (the following

Design outcomes

Primary

MeasureTime frameDescription
Characterize Immunoglobulin fragment crystallization modifications4 WeeksUse mass spectrometry and RNA sequencing from subject blood samples to characterize site specific glycosylation on Immunoglobulin A, Immunoglobulin M, and Immunoglobulin G.

Secondary

MeasureTime frameDescription
Assess for potential adverse events2 months after first doseMonitor symptoms, severity, and duration of adverse events.
Quantification of enzymatic modifications measured in grams by spectrometry6 monthsThe investigators will measure enzymatic changes on glycoproteins in the immune system by spectrometry, i.e., these changes will be measured in grams. Spectometry will allow the investigators to quantify these changes in small detail, and therefore give a better idea of how supplementation can change enzymatic process that then affect the structure, and mass, of glycoproteins.
Flow cytometry to determine the effect of dietary supplementation on the immune system6 monthsPerform flow cytometry on subject blood samples to determine the effect of dietary supplement on immune system. For example, the investigators will note changes to immune cell pro-inflammatory and anti-inflammatory cytokine clusters as translated proteins (measured as height and area of cytokine intensity).
Transcriptome analysis to determine the effect of dietary supplementation on the immune system6 monthsPerform transcriptome analysis on subject blood samples to determine the effect of dietary supplement on immune system. For example, the investigators will note changes to immune cell pro-inflammatory and anti-inflammatory cytokine clusters as RNA (measure on a logarithmic scale per number of reads) to determine the effects of supplementation on both gene transcription and translation.

Countries

United States

Contacts

CONTACTEmanual Maverakis, MD
emaverakis@ucdavis.edu916-551-2635
PRINCIPAL_INVESTIGATOREmanual Maverakis, MD

University of California, Davis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026